Captor Therapeutics (CTX) Q2 2024 earnings summary

Executive summary

• Clinical trial application for CT-01 in liver cancer submitted in Europe in August 2024, with rapid site recruitment and marking a key milestone.

• CT-02 and CT-03 programs advancing, with in-vivo proof of concept for CT-02 and strong non-human primate data for CT-03.

• Revenue from R&D services rose to PLN 9.3M in H1 2024, up from PLN 3.9M year-over-year, driven by commercial collaborations.

• Net loss narrowed to PLN 19.4M in H1 2024 from PLN 43.3M in H1 2023, reflecting reduced preclinical expenditures.

• Cash position at June 30, 2024, was PLN 56.5M, supporting ongoing operations and development.

Financial highlights

• Total revenue (including grants and financial income) was PLN 12.6M in H1 2024, down from PLN 14.6M in H1 2023 due to lower grant income.

• Grant revenues decreased from PLN 8.0M to PLN 2.5M year-over-year.

• Operating expenses decreased to PLN 31.2M from PLN 46.8M year-over-year, mainly due to lower third-party and consulting costs.

• Operational cash outflow reduced from PLN 31.5M in H1 2023 to PLN 17.5M in H1 2024.

• No dividends were paid or proposed.

Outlook and guidance

• Awaiting regulatory review for CT-01 clinical trial application under centralized procedure.

• Losses are expected to continue as R&D projects progress, but commercial partnerships are anticipated to offset reduced grant income.

• New grant applications are in progress, and additional funding sources, including capital raises, are under consideration for 2025.

• Management is confident in the company’s ability to meet obligations for at least 12 months post-report.

• Continued focus on advancing lead clinical programs and business development partnerships.